Passage Bio shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $7 Price Target.
Portfolio Pulse from Benzinga Newsdesk
Passage Bio shares increased after Rodman & Renshaw initiated coverage with a Buy rating and a $7 price target.

September 03, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Passage Bio shares are trading higher following a Buy rating and a $7 price target from Rodman & Renshaw.
The initiation of coverage with a Buy rating and a specific price target by a financial firm often leads to increased investor interest and confidence, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100